Avid Bioservices Inc (CDMO)

[Thurly]

Regarding the synergistic action of docetaxel and bavi, I found this abstract on PubMed:

http://www.ncbi.nlm.nih.gov/pubmed/15899833
Treatment of mice bearing orthotopic MDA-MB-435 human breast tumors with 3G4 plus docetaxel inhibited tumor growth by 93%. Treatment of mice bearing disseminated MDA-MB-435 tumors with 3G4 plus docetaxel reduced the average number of tumor colonies in the lungs by 93% and half the animals did not develop tumors. In both tumor models, the antitumor effect of the combination was statistically superior (P < 0.01) to that of docetaxel or 3G4 alone. Combination therapy reduced the tumor vessel density and plasma volume in tumors to a greater extent than did the individual drugs. The combination therapy was no more toxic to the mice than was docetaxel alone.

The same thing with prostate cancer:
http://www.drugs.com/clinical_trials/data-presented-aacr-annual-meeting-shows-bavituximab-equivalent-plus-docetaxel-reduces-tumor-growth-3920.html
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

93%, 93%, 95%

It may be a combination that works particularly well in a variety of cancers.